K Gordon-Smith1, L A Jones, S M Burge, C S Munro, S Tavadia, N Craddock. 1. Department of Psychological Medicine, The Henry Wellcome Building for Biomedical Research in Wales, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, U.K.
Abstract
BACKGROUND: Darier disease (DD) is a rare autosomal dominantly inherited skin disorder in which co-occurrence of neuropsychiatric abnormalities has been frequently reported by dermatologists. It is caused by mutations in a single gene, ATP2A2, which is expressed in the skin and brain. OBJECTIVES: To conduct the first systematic investigation of the neuropsychiatric phenotype in DD. METHODS: One hundred unrelated individuals with DD were assessed using a battery of standardized neuropsychiatric measures. Data were also obtained on a number of clinical features of DD. RESULTS: Individuals with DD were found to have high lifetime rates of mood disorders (50%), specifically major depression (30%) and bipolar disorder (4%), and suicide attempts (13%) and suicidal thoughts (31%). These were more common in DD when compared with general population data. The prevalence of epilepsy (3%) in the sample was also higher than the prevalence in the general population. There was no consistent association of specific dermatological features of DD and presence of psychiatric features. CONCLUSIONS: These findings highlight the need for clinicians to assess and recognize neuropsychiatric symptoms in DD. The results do not suggest that neuropsychiatric symptoms are simply a psychological reaction to having a skin disease, but are consistent with the pleiotropy hypothesis that mutations in the ATP2A2 gene, in addition to causing DD, confer susceptibility to neuropsychiatric features. Further research is needed to investigate genotype-phenotype correlations between the types and/or locations of pathogenic mutations within ATP2A2 and the expressed neuropsychiatric phenotypes.
BACKGROUND: Darier disease (DD) is a rare autosomal dominantly inherited skin disorder in which co-occurrence of neuropsychiatric abnormalities has been frequently reported by dermatologists. It is caused by mutations in a single gene, ATP2A2, which is expressed in the skin and brain. OBJECTIVES: To conduct the first systematic investigation of the neuropsychiatric phenotype in DD. METHODS: One hundred unrelated individuals with DD were assessed using a battery of standardized neuropsychiatric measures. Data were also obtained on a number of clinical features of DD. RESULTS: Individuals with DD were found to have high lifetime rates of mood disorders (50%), specifically major depression (30%) and bipolar disorder (4%), and suicide attempts (13%) and suicidal thoughts (31%). These were more common in DD when compared with general population data. The prevalence of epilepsy (3%) in the sample was also higher than the prevalence in the general population. There was no consistent association of specific dermatological features of DD and presence of psychiatric features. CONCLUSIONS: These findings highlight the need for clinicians to assess and recognize neuropsychiatric symptoms in DD. The results do not suggest that neuropsychiatric symptoms are simply a psychological reaction to having a skin disease, but are consistent with the pleiotropy hypothesis that mutations in the ATP2A2 gene, in addition to causing DD, confer susceptibility to neuropsychiatric features. Further research is needed to investigate genotype-phenotype correlations between the types and/or locations of pathogenic mutations within ATP2A2 and the expressed neuropsychiatric phenotypes.
Authors: Saurav Guha; Elliott Rees; Ariel Darvasi; Dobril Ivanov; Masashi Ikeda; Sarah E Bergen; Patrik K Magnusson; Paul Cormican; Derek Morris; Michael Gill; Sven Cichon; Jeffrey A Rosenfeld; Annette Lee; Peter K Gregersen; John M Kane; Anil K Malhotra; Marcella Rietschel; Markus M Nöthen; Franziska Degenhardt; Lutz Priebe; René Breuer; Jana Strohmaier; Douglas M Ruderfer; Jennifer L Moran; Kimberly D Chambert; Alan R Sanders; Jianxin Shi; Kenneth Kendler; Brien Riley; Tony O'Neill; Dermot Walsh; Dheeraj Malhotra; Aiden Corvin; Shaun Purcell; Pamela Sklar; Nakao Iwata; Christina M Hultman; Patrick F Sullivan; Jonathan Sebat; Shane McCarthy; Pablo V Gejman; Douglas F Levinson; Michael J Owen; Michael C O'Donovan; Todd Lencz; George Kirov Journal: JAMA Psychiatry Date: 2013-03 Impact factor: 21.596
Authors: Anna Celli; Donald S Mackenzie; Yongjiao Zhai; Chia-Ling Tu; Daniel D Bikle; Walter M Holleran; Yoshikazu Uchida; Theodora M Mauro Journal: J Invest Dermatol Date: 2012-01-26 Impact factor: 8.551
Authors: Philip Curman; Johanna Bern; Linnea Sand; Martin Cederlöf; Etty Bachar-Wikström; Jakob D Wikström Journal: Acta Derm Venereol Date: 2021-06-22 Impact factor: 3.875
Authors: Jeane Jeong Hoon Yang; Roberta Simão Lopes; Medéia Carolina Fernandes Pereira; Antonio Jose Tebcherani; Mário Cezar Pires Journal: An Bras Dermatol Date: 2015 May-Jun Impact factor: 1.896